Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasms × carfilzomib × Clear all

Phase

Phase 1 4 Phase 2 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 60 Recurrence 10 Neoplasms, Plasma Cell 7 Waldenstrom Macroglobulinemia 4 Smoldering Multiple Myeloma 4 Lymphoma, Mantle-Cell 2 Salivary Gland Adenoma, Pleomorphic 1 Renal Insufficiency 1 Prostatic Neoplasms 1 Neoplasms 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma 1 Kidney Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Neuroendocrine 1 Carcinoid Tumor 1

Interventions

Bevacizumab 47 Gemcitabine 46 Cyclophosphamide 43 Carboplatin 37 Docetaxel 36 Fluorouracil 33 Cisplatin 33 Paclitaxel 31 pembrolizumab 30 Oxaliplatin 27 Radiotherapy 25 Irinotecan 25 Capecitabine 25 Leucovorin 23 Dexamethasone 23 Cetuximab 21 Nivolumab 20 Doxorubicin 19 Pemetrexed 18 Drug Therapy 18 Erlotinib Hydrochloride 17 Trastuzumab 15 Rituximab 15 Prednisone 15 durvalumab 14 atezolizumab 14 Lapatinib 14 trametinib 13 fludarabine 13 Sorafenib 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04263480 2025-04-04

CZAR-1

University of Ulm

Phase 2 Active not recruiting

Waldenstrom Macroglobulinemia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡